Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 [Yahoo! Finance]
Q32 Bio Inc. (QTTB)
Company Research
Source: Yahoo! Finance
ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued clinical advancement of ADX-097 -- WALTHAM, Mass. Oct. 14, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that it will present clinical data supporting its program for innate immunity, ADX-097, at the American Society of Nephrology (ASN) Kidney Week 2024, taking place October 24-27, 2024 , in San Diego, Calif. Abstracts are available here . ADX-097, Q32 Bio's lead product candidate from its tissue-targeted complement inhibitor platform, is a humanized anti-C3d mAb fusion protein being evaluated for the treatment of patients with renal diseases associated with increased complement activation. "We look forward to presenting our promising clinical data at ASN Kidney Week 2024 that supports the continued advancement of ADX-097,
Show less
Read more
Impact Snapshot
Event Time:
QTTB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QTTB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QTTB alerts
High impacting Q32 Bio Inc. news events
Weekly update
A roundup of the hottest topics
QTTB
News
- Q32 Bio Inc. (NASDAQ: QTTB) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $90.00 price target on the stock.MarketBeat
- Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024PR Newswire
- Q32 Bio Inc. (NASDAQ: QTTB) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $95.00 price target on the stock.MarketBeat
- Q32 Bio to Participate in Upcoming September Investor ConferencesPR Newswire
- Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097 [Seeking Alpha]Seeking Alpha
QTTB
Earnings
- 8/8/24 - Miss
QTTB
Sec Filings
- 10/25/24 - Form SC
- 10/16/24 - Form 4
- 10/10/24 - Form 4
- QTTB's page on the SEC website